Neovascular Age-related Macular Degeneration Clinical Trials in Augusta, Georgia
8 recruitingAugusta, Georgia
Showing 1–8 of 8 trials
Recruiting
Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled51 locationsNCT04853251
Recruiting
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting
Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
AbbVie561 enrolled128 locationsNCT07007065
Recruiting
Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled46 locationsNCT07482176
Recruiting
Phase 3
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research600 enrolled65 locationsNCT05904028
Recruiting
Phase 1Phase 2
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-Related Macular Degeneration (nAMD)
Alcon Research140 enrolled42 locationsNCT05769153
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Sanofi66 enrolled18 locationsNCT06660667
Recruiting
Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577